Woodstock Corp’s Ultragenyx Pharmaceutical RARE Stock Holding History

Woodstock Corp’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$307K	Buy	+9,191	New	+$228K	0.03%	137
2025 Q4	–	Sell	-18,114	Closed	-$545K	–	158
2025 Q3	$545K	Buy	18,114 +4,827	+36%	+$145K	0.05%	116
2025 Q2	$483K	Sell	13,287 -584	-4%	-$21.1K	0.04%	118
2025 Q1	$502K	Hold	13,871	–	–	0.05%	116
2024 Q4	$584K	Hold	13,871	–	–	0.06%	113
2024 Q3	$771K	Hold	13,871	–	–	0.07%	107
2024 Q2	$570K	Buy	13,871 +2,747	+25%	+$117K	0.06%	113
2024 Q1	$519K	Buy	11,124 +3,064	+38%	+$145K	0.05%	119
2023 Q4	$385K	Buy	+8,060	New	+$312K	0.04%	129
2019 Q4	–	Sell	-11,212	Closed	-$480K	–	157
2019 Q3	$480K	Hold	11,212	–	–	0.08%	120
2019 Q2	$712K	Hold	11,212	–	–	0.12%	105
2019 Q1	$778K	Buy	+11,212	New	+$641K	0.14%	102

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Woodstock Corp's RARE Position: Q2 2026 in Review

Woodstock Corp opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 9,191 shares worth $307K. The stake represents 0.03% of the portfolio and ranks #137 among its holdings. This is a return to the name: Woodstock Corp previously reported a position in RARE as recently as Q3 2025.

Woodstock Corp first reported a position in RARE in Q1 2019 and has held it in 12 quarters since. The position peaked at $778K in Q1 2019. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Woodstock Corp held 9,191 shares of Ultragenyx Pharmaceutical worth $307K as of Q2 2026.
Ultragenyx Pharmaceutical was a new Woodstock Corp position in Q2 2026.
Ultragenyx Pharmaceutical made up 0.03% of Woodstock Corp's portfolio in Q2 2026, its #137 holding.
Woodstock Corp first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and has held it in 12 quarters since.
Woodstock Corp's Ultragenyx Pharmaceutical position peaked at $778K in Q1 2019.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Woodstock Corp's 13F filing for Q2 2026, filed 13 Jul 2026.